TOI Q3 revenue up 22% to $99.9M; net loss narrows to $16.1M, adjusted EBITDA -$8.2M

Oncology Institute, Inc.

2024-Q3 EPS reported -$0.56 revenue$293,145,000

Revenue $99.9M (+21.8% YoY), driven by dispensary revenue surge of 79.9%.
Gross profit $14.4M (-10.1% YoY); SG&A reduced 6% to $26.6M.
Net loss $16.1M ($0.18 EPS) vs $17.4M loss in Q3 2023.
Adjusted EBITDA -$8.2M vs -$5.3M in prior year period.
Board completed strategic review; elected to continue current plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.